Search

Displaying results 7571 - 7580 of 10000 in total
  1. Drug

    Elsiglutide

    go.drugbank.com/drugs/DB06336
    Investigational

  2. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  3. Drug

    Diaminopyrimidine oxide

    go.drugbank.com/drugs/DB18756
    Approved

    Diaminopyrimidine oxide is a compound similar to [minoxidil] which is used to aid in hair growth.

  4. Drug

    Isoxicam

    go.drugbank.com/drugs/DB08942
    ApprovedWithdrawn

    Isoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.

  5. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  6. Drug

    IRX-5183

    go.drugbank.com/drugs/DB05653
    Investigational

  7. Drug

    AN0128

    go.drugbank.com/drugs/DB05054
    Investigational

    Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents. … AN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis.

  8. Drug

    Avexitide

    go.drugbank.com/drugs/DB14806
    ApprovedInvestigationalWithdrawn

    Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).

  9. Drug

    Radotinib

    go.drugbank.com/drugs/DB12323
    Investigational

    Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

  10. Drug

    ARG201

    go.drugbank.com/drugs/DB06621
    Experimental

    This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma) … ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc).